Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer

J. N. Ingle; S. J. Green; D. L. Ahmann; H. J. Long; J. H. Edmonson; J. Rubin; M. N. Chang; E. T. Creagan

doi:10.1200/JCO.1986.4.6.958

Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer

J. N. Ingle, S. J. Green, D. L. Ahmann, H. J. Long, J. H. Edmonson, J. Rubin, M. N. Chang, E. T. Creagan

Medical Oncology

Research output: Contribution to journal › Article › peer-review

58 Scopus citations

Abstract

A randomized clinical trial was performed to compare the efficacy of tamoxifen (TAM) alone with that of TAM plus aminoglutethimide (AG) and hydrocortisone (HC). Patients failing TAM could receive AG and HC. Objective responses to therapy were seen in 21 of 49 TAM patients (43%) and 25 of 51 TAM, AG and HC patients (49%). Time to disease progression and survival distributions were not significantly different between the treatment arms. Toxicity was greater for patients treated with TAM, AG, and HC and the trial was discontinued early for this reason. Twenty-four patients received AG and HC after TAM therapy and three (12%) achieved a response. We conclude that the combination of TAM, AG, and HC is not recommended over TAM alone because toxicity appears to outweigh any potential therapeutic advantage.

Original language	English (US)
Pages (from-to)	958-964
Number of pages	7
Journal	Journal of Clinical Oncology
Volume	4
Issue number	6
DOIs	https://doi.org/10.1200/JCO.1986.4.6.958
State	Published - 1986

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1200/JCO.1986.4.6.958

Cite this

@article{45c5390cac4f4bd69e090321afbc35f4,

title = "Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer",

abstract = "A randomized clinical trial was performed to compare the efficacy of tamoxifen (TAM) alone with that of TAM plus aminoglutethimide (AG) and hydrocortisone (HC). Patients failing TAM could receive AG and HC. Objective responses to therapy were seen in 21 of 49 TAM patients (43%) and 25 of 51 TAM, AG and HC patients (49%). Time to disease progression and survival distributions were not significantly different between the treatment arms. Toxicity was greater for patients treated with TAM, AG, and HC and the trial was discontinued early for this reason. Twenty-four patients received AG and HC after TAM therapy and three (12%) achieved a response. We conclude that the combination of TAM, AG, and HC is not recommended over TAM alone because toxicity appears to outweigh any potential therapeutic advantage.",

author = "Ingle, {J. N.} and Green, {S. J.} and Ahmann, {D. L.} and Long, {H. J.} and Edmonson, {J. H.} and J. Rubin and Chang, {M. N.} and Creagan, {E. T.}",

year = "1986",

doi = "10.1200/JCO.1986.4.6.958",

language = "English (US)",

volume = "4",

pages = "958--964",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "6",

}

TY - JOUR

T1 - Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer

AU - Ingle, J. N.

AU - Green, S. J.

AU - Ahmann, D. L.

AU - Long, H. J.

AU - Edmonson, J. H.

AU - Rubin, J.

AU - Chang, M. N.

AU - Creagan, E. T.

PY - 1986

Y1 - 1986

N2 - A randomized clinical trial was performed to compare the efficacy of tamoxifen (TAM) alone with that of TAM plus aminoglutethimide (AG) and hydrocortisone (HC). Patients failing TAM could receive AG and HC. Objective responses to therapy were seen in 21 of 49 TAM patients (43%) and 25 of 51 TAM, AG and HC patients (49%). Time to disease progression and survival distributions were not significantly different between the treatment arms. Toxicity was greater for patients treated with TAM, AG, and HC and the trial was discontinued early for this reason. Twenty-four patients received AG and HC after TAM therapy and three (12%) achieved a response. We conclude that the combination of TAM, AG, and HC is not recommended over TAM alone because toxicity appears to outweigh any potential therapeutic advantage.

AB - A randomized clinical trial was performed to compare the efficacy of tamoxifen (TAM) alone with that of TAM plus aminoglutethimide (AG) and hydrocortisone (HC). Patients failing TAM could receive AG and HC. Objective responses to therapy were seen in 21 of 49 TAM patients (43%) and 25 of 51 TAM, AG and HC patients (49%). Time to disease progression and survival distributions were not significantly different between the treatment arms. Toxicity was greater for patients treated with TAM, AG, and HC and the trial was discontinued early for this reason. Twenty-four patients received AG and HC after TAM therapy and three (12%) achieved a response. We conclude that the combination of TAM, AG, and HC is not recommended over TAM alone because toxicity appears to outweigh any potential therapeutic advantage.

UR - http://www.scopus.com/inward/record.url?scp=0022544986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022544986&partnerID=8YFLogxK

U2 - 10.1200/JCO.1986.4.6.958

DO - 10.1200/JCO.1986.4.6.958

M3 - Article

C2 - 3519885

AN - SCOPUS:0022544986

SN - 0732-183X

VL - 4

SP - 958

EP - 964

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 6

ER -

Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this